<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The innate immune cells, invariant natural killer T cells (iNKT cells), are implicated in the pathogenesis of <z:hpo ids='HP_0003765'>psoriasis</z:hpo>, an inflammatory condition associated with <z:hpo ids='HP_0001513'>obesity</z:hpo> and other <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e>, such as <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We observed an improvement in <z:hpo ids='HP_0003765'>psoriasis</z:hpo> severity in a patient within days of starting treatment with an incretin-mimetic, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>This was independent of change in glycaemic control </plain></SENT>
<SENT sid="3" pm="."><plain>We proposed that this unexpected clinical outcome resulted from a direct effect of GLP-1 on iNKT cells </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We measured circulating and <z:e sem="disease" ids="C0920235" disease_type="Disease or Syndrome" abbrv="">psoriatic plaque</z:e> iNKT cell numbers in two patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0003765'>psoriasis</z:hpo> before and after commencing GLP-1 analogue therapy </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, we investigated the in vitro effects of GLP-1 on iNKT cells and looked for a functional GLP-1 receptor on these cells </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The <z:hpo ids='HP_0003765'>Psoriasis</z:hpo> Area and Severity Index improved in both patients following 6Â weeks of GLP-1 analogue therapy </plain></SENT>
<SENT sid="7" pm="."><plain>This was associated with an alteration in iNKT cell number, with an increased number in the circulation and a decreased number in <z:e sem="disease" ids="C0920235" disease_type="Disease or Syndrome" abbrv="">psoriatic plaques</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The GLP-1 receptor was expressed on iNKT cells, and GLP-1 induced a dose-dependent inhibition of iNKT cell cytokine secretion, but not cytolytic degranulation in vitro </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: The clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as <z:hpo ids='HP_0003765'>psoriasis</z:hpo> </plain></SENT>
</text></document>